Phase I and translational study of capecitabine, cisplatin, and irinotecan in patients with solid tumors.

被引：0
|
作者：
Verschraegen, CF [1 ]
Lee, FC [1 ]
Rabinowitz, I [1 ]
Mangalik, A [1 ]
Jennings, C [1 ]
Maestas, A [1 ]
Shen, Z [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2114
引用
收藏
页码：155S / 155S
页数：1
相关论文
共 50 条
  • [1] Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors.
    Krishnamurthi, SS
    Brell, JM
    Coviello, KM
    Dowlati, A
    Egorin, MJ
    Hoppel, CL
    Ingails, ST
    Ivy, SP
    Li, X
    Remick, SC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 154S - 154S
  • [2] Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies
    H. Sayar
    Z. Shen
    S. J. Lee
    M. Royce
    I. Rabinowitz
    F. Lee
    H. Smith
    S. Eberhardt
    A. Maestas
    H. Lu
    C. Verschraegen
    Investigational New Drugs, 2009, 27 : 153 - 158
  • [3] Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies
    Sayar, H.
    Shen, Z.
    Lee, S. J.
    Royce, M.
    Rabinowitz, I.
    Lee, F.
    Smith, H.
    Eberhardt, S.
    Maestas, A.
    Lu, H.
    Verschraegen, C.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 153 - 158
  • [4] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [5] A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors.
    Furman, WL
    Daw, NC
    Crews, KR
    Stewart, CF
    McCarville, B
    Santana, VM
    Hawkins, D
    Rodriguez-Galindo, C
    Navid, F
    Houghton, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 804S - 804S
  • [6] Phase I dose-finding study of capecitabine (X) with escalating irinotecan (I) and oxaliplatin (O) in patients (pts) with previously treated solid tumors.
    Samanta, E
    Rigatos, SK
    Triantafillis, M
    Kourtis, S
    Koutsourakis, G
    Papanikitas, K
    Konstantinopoulou, A
    Koussoulas, V
    Aravantinos, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [7] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
    Rangwala, Fatima A.
    Bendell, Johanna C.
    Kozloff, Mark
    Arrowood, Christy
    Meadows, Jennifer
    Tourt-Uhlig, Sandra Ellen
    Murphy, Jennifer
    Meadows, Kellen
    Morse, Michael
    Uronis, Hope Elizabeth
    Hsu, Shiaowen David
    Zafar, Yousuf
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [8] Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors
    Nakanishi, Y
    Takayama, K
    Wataya, H
    Izumi, M
    Minami, T
    Takano, K
    Inoue, K
    Osaki, S
    Kimotsuki, K
    Harada, T
    Hara, N
    CHEMOTHERAPY, 2002, 48 (04) : 205 - 210
  • [9] Phase I dose escalation and safety study of a semi-solid matrix (SSM) formulation of oral irinotecan and capecitabine tablets in patients with advanced solid tumors.
    Benson, AIB
    Rubin, E
    Beers, S
    Mucci-Lorusso, P
    Vermuelen, W
    Denis, L
    Compton, L
    Pavlov, D
    Rothenberg, ML
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 137S - 137S
  • [10] Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
    Casanova, Michela
    Bautista, Francisco
    Hewson, Quentin Campbell
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld
    Canete, Adela
    Corradini, Nadege
    Ploeger, Bart
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John Woojune
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345